Flyer
Bispecific antibody service
Bispecific Antibody Discovery Service
One-stop solution for bsAb discovery
Extensive experience in major Bispecific Antibody (bsAb) formats, ProBio provides one-stop bsAb
discovery solution from target discovery to preclinical candidates(PCC), including bsAb format design
in vitro
for different MOA and target , bsAb construction and expression,
efficacy study and developability.
functional validation, in vivo
Excellent bsAb track
record
Customized bsAb
formats
One-stop bsAb
discovery solution
Over 110 bsAb discovery projects
Compatible with almost any mAb
From target to PCC
and bsAb sequence
Provide insight and suggestion
based on the target, MOA and
existing antibody candidates
Comprehensive antibody
discovery platform
Most advanced project is in clinical
phase 3
Comprehensive antibody
discovery platform
NO license fee
Obtain best-in-class bsAb PCC in 6 months
4
12
weeks
16-20
weeks
weeks
In vivo assay
Design & Construction
Functional Validation
Developability
Affinity
Format
Epitope
Valency
Linker
in vivoefficacy
PK profile
Binding
Blocking
In vitro assay
Temperature stability
pH stability
Freeze-thaw stability
Titer
Compatible with almost any mAb and sdAb sequence
BiTE
Crossmab KIH
Duobody
IgG-scFv
SMABody
Asymmetric 2+1
Building Block
scFv
IgG
IgG
IgG+scFv
IgG+sdAb
sFab-IgG+Fab/sdAb/scFv
Fc mutation
CH3 KIH mutations based
H chain heterodimerization
Antigen-recognition fragment
is fused on N-terminus of Fc
in either monovalent or bivalent
fasion.
Production of parental
monoclonal antibody,
followed by in vitro
assembly in certain
condition.
CH3 KIH mutations based
H chain heterodimerization
Exchange of CH1 and CL
to avoid L chain mis-pair
scFv fused with IgG based
Tetravalent BsAb
sdAb fused with IgG
based Tetravalent BsAb
scFv fused with scFv
Protein Engineering
Non-IgG like
protein scaffold
Asymmetric
1+1
Asymmetric
1+1
Symmetric
2+2
Symmetric
2+2
Asymmetric
2+1
Structure
Ab purification1
Retaining of parental Ab
activity2
ProBio also has expertise in the discovery and development research of other novel bispecific antibody formats
1. The greater the number of " " symbols in the cell, the easier it is to purify the antibody.
2. The greater the number of " " symbols in the cell, the higher the retention of the parental antibody's activity.
ProBioCDMO.com
+1-732-885-9188
Accelerating Ideas. Delivering Impact.
4 types of bsAb bioassay platforms based on MOA
ProBio offers 4 categories of bsAb bioassays solutions for bsAbs screening and characterizing.
200+tumor cell lines,200+overexpressing cell lines,10+ reporter gene cell lines available for bsAb
validation
Delivered40+bsAb bioassay projects
Cell-engager
and redirectors)
Targets on
Target Cell
Targets on
Effector Cell
In Vitro Assay
Target Cell
Types of bsAbs
(Tumor-targeted effector cell immunomodulators
Effector Cell
1. Primary immune cell assay(TDCC etc)
2. Cytokines release assay
3. Reporter cell line assay
T cell engager
CD3
Targets on Effector Cell
(CD3, CD16A, 4-1BB etc.)
Targets on Target Cell
(TAA/TSA)
1. Primary
cells(T cell /NK
cell/macro -
phage/DC
etc.)
NK cell activating
receptors (CD16A,
NKG2D, NKp46,
NKp30 etc.)
1. Target
1. Primary immune cell assay
(tumor cell killing with primary NK etc.)
2. Reporter cell line assay
overexpress-
ing engineered
cell lines
NK cell engager
TAA/TSA
1. Reporter cell line assay
Co-stimulatory
immune checkpoint
(CD40, 4-1BB, CD28
etc.)
Anti-TAA x co-
stimulatory
2. Primary immune cell assay(immune
cell activation, tumor cell killing, mixed
lymphocyte reaction (MLR) etc.)
2. Reporter
2. Tumor cell
Immune
cells
cell lines
lines
immune checkpoint
Tumor cells
Perforin/ granzymes
NK cell activating
receptor CD16A,
1. Reporter cell line assay
2. Primary immune cell assay (ADCP
etc.)
Anti-TAA x TAA/co-
inhibitory immune
checkpoint
macrophage activating
receptor CD32A
Dual-target blockade
Types of BsAbs
Targets
In Vitro Assay
Target 1:
Target 2:
Different targets (IL17A,
c-Met etc.)
Different targets
(TNF-α, EGFR etc.)
Different epitopes
on the same
VEGF & ANG2, Her2 & Her2, EGFR &
1. Cell signaling pathway assay
2. Reporter cell line assay
3. Enzyme activity assay
4. Cytokines/chemokines
release assay
Blocking angiogenesis and/or tumorigenesis
c-Met, VEGF & DLL4 etc.
Different epitopes
on the same
target (Her2 etc.)
TGFβ & PDL1, TGFβ & CD73, TGFβ &
Modulating tumor microenvironment (TME)
target (Her2 etc.)
CD39 etc.
5. Antibody internalization assay
6. Cell proliferation assay
7. Primary immune cell assay
(ADCC, MLR etc.)
TNFα & IL17A, IL4 & IL13, BAFF &
Targeting inflammatory/autoimmune diseases
IL17A etc.
Cells
locking angiogenesis and/or tumorigenesis x
Anti-immune checkpoint
VEGF & PD1, EGFR & PD1, Her2 &
PD1 etc.
Immune cell activation
(Dual immunomodulators )
Types of BsAbs
Targets
In Vitro Assay
Target 1:
Target 2:
co-inhibitory immune
checkpoint
co-inhibitory immune
checkpoint
Anti-co-inhibitory immune checkpoint ×
co-inhibitory immune checkpoint
PD1 & TIGIT, PD1 & CTLA4 etc..
PD1 & 4-1BB, PD1 & OX40 etc..
(PD1, CTLA4 etc.)
co-stimulatory immune
checkpoint
(PD1, CTLA4 etc.)
co-stimulatory immune
checkpoint
1. Reporter cell line assay
2. Primary immune cell
assay (immune cell
Anti-co-inhibitory immune checkpoint ×
co-stimulatory immune checkpoint
(4-1BB, OX40 etc.)
(4-1BB, OX40 etc.)
activation, MLR etc.)
Immune cells
Anti-co-stimulatory immune checkpoint ×
co-stimulatory immune checkpoint
4-1BB & CD40, 4-1BB & OX40 etc..
Cell surface protein bridging
(Triggers cellular signaling pathway)
TRAILR2
TAA/TSA
TAA/TSA
Types of BsAbs
Apoptotic signaling pathway
Coagulation pathway
Targets
In Vitro Assay
Activation of apoptosis pathway
DR5 & TAA etc.
Cell activity assay
Factor X
Factor IXa
Coagulation time determination
Factors IXa & Factors X
Activation of coagulation cascade